Deng John, Wool Julia, Montecino Ronald Blanco, Arbaiza Alvaro Cadillo, Xie Luyu, Messiah Sarah E, Matthew Sunil, Shiffer Shannon, Almandoz Jaime P, Tavakkoli Anna
The University of Texas Southwestern Medical Center, Dallas, USA.
St. Barnabas Hospital, The Bronx, USA.
Obes Surg. 2025 Feb;35(2):582-586. doi: 10.1007/s11695-024-07665-9. Epub 2025 Jan 8.
Recurrent weight gain after laparoscopic sleeve gastrectomy (LSG) is common. Revisional endoscopic sleeve gastroplasty (r-ESG) has been shown to be a promising endoscopic bariatric therapy (EBT) to treat weight recurrence after LSG. However, to date, weight loss outcomes beyond 1-year follow-up are unknown. Our study aims as follows: (1) examine 1 year, 18-month, and 24-month weight loss outcomes post-r-ESG and (2) determine if weight loss outcomes post-LSG predict clinical outcomes post-r-ESG.
This was a retrospective cohort data of patients who completed r-ESG from December 2020 to November 2023. The primary outcome was percentage of total body weight loss (TBWL) at 1-year post-r-ESG. Secondary outcomes included TBWL at 18- and 24-month post-r-ESG. Multivariable logistic regression analysis was used to determine predictors of weight loss ≥ 5% at 12 months.
A total of 55 patients completed r-ESG. TBWL post-r-ESG at 12 months was 8.6% (n = 37), at 18 months was 10.7% (n = 31), and at 24 months was 12.6% (n = 18) (Table 2). There were no statistically significant variables associated with weight loss ≥ 5% at 12 months (Table 3).
Our study demonstrates that r-ESG is an effective and durable EBT for post-LSG weight recurrence. Further research is needed to determine optimal timing of r-ESG for weight recurrence as well as the adjunctive role of anti-obesity medications.
腹腔镜袖状胃切除术（LSG）后体重反复增加很常见。修订版内镜袖状胃成形术（r-ESG）已被证明是一种有前景的内镜减重治疗方法（EBT），用于治疗LSG后的体重复发。然而，迄今为止，超过1年随访期的减重效果尚不清楚。我们的研究目的如下：（1）检查r-ESG术后1年、18个月和24个月的减重效果；（2）确定LSG术后的减重效果是否能预测r-ESG术后的临床效果。
这是一项对2020年12月至2023年11月完成r-ESG的患者的回顾性队列数据研究。主要结局是r-ESG术后1年时总体重减轻百分比（TBWL）。次要结局包括r-ESG术后18个月和24个月时的TBWL。采用多变量逻辑回归分析来确定12个月时体重减轻≥5%的预测因素。
共有55例患者完成了r-ESG。r-ESG术后12个月时的TBWL为8.6%（n = 37），18个月时为10.7%（n = 31），24个月时为12.6%（n = 18）（表2）。12个月时，没有与体重减轻≥5%相关的具有统计学意义的变量（表3）。
我们的研究表明，r-ESG是治疗LSG术后体重复发的一种有效且持久的EBT。需要进一步研究来确定r-ESG治疗体重复发的最佳时机以及抗肥胖药物的辅助作用。
